NCT05603754: An ongoing trial by Biosplice Therapeutics, Inc.
This trial is completed, but has been granted a delay in reporting its results.
It must report results 1 year, 2 months from now.
Full data
| Full entry on ClinicalTrials.gov | NCT05603754 |
|---|---|
| Title | A Phase 3, 16-Week, Multicenter, Randomized, Double Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of a Single Injection of Lorecivivint 0.07 mg Dose in the Target Knee Joint of Subjects With Moderate to Severe Osteoarthritis Pain of the Knee |
| Results Status | Ongoing |
| ACT or pACT? | This is what FDAAA officially calls an "Applicable Clinical Trial" |
| Start date | Nov. 18, 2022 |
| Completion date | Feb. 20, 2024 |
| Required reporting date | Feb. 20, 2027, midnight |
| Actual reporting date | None |
| Date last checked at ClinicalTrials.gov | Dec. 5, 2025 |
| Days late | None |